<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ccr371818" xml:lang="en" article-type="case-study" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Clin Case Rep</journal-id><journal-id journal-id-type="pmc-domain-id">2542</journal-id><journal-id journal-id-type="pmc-domain">ccr</journal-id><journal-id journal-id-type="publisher-id">CCR3</journal-id><journal-title-group><journal-title>Clinical Case Reports</journal-title></journal-title-group><issn pub-type="epub">2050-0904</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12778412</article-id><article-id pub-id-type="pmcid-ver">PMC12778412.1</article-id><article-id pub-id-type="pmcaid">12778412</article-id><article-id pub-id-type="pmcaiid">12778412</article-id><article-id pub-id-type="pmid">41509085</article-id><article-id pub-id-type="doi">10.1002/ccr3.71818</article-id><article-id pub-id-type="publisher-id">CCR371818</article-id><article-id pub-id-type="other">CCR3-2025-09-3691.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="article-subject-classification"><subject>Endocrinology and Metabolic Disorders</subject></subj-group><subj-group subj-group-type="article-subject-classification"><subject>Cardiovascular Disorders</subject></subj-group><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Euglycemic Ketoacidosis Induced by Dapagliflozin in a Non&#8208;Diabetic Patient With Cardiac Amyloidosis</article-title></title-group><contrib-group><contrib id="ccr371818-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Hamoud</surname><given-names initials="SAS">Salhamoud Abdelfatah Saleh</given-names></name><xref rid="ccr371818-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>salhamoud@hotmail.com</email></address></contrib><contrib id="ccr371818-cr-0002" contrib-type="author"><name name-style="western"><surname>Harding</surname><given-names initials="E">Ellie</given-names></name><xref rid="ccr371818-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="ccr371818-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>University Hospitals Plymouth NHS Trust</institution>
<city>Plymouth</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Salhamoud Abdelfatah Saleh Hamoud (<email>salhamoud@hotmail.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>14</volume><issue seq="1510">1</issue><issue-id pub-id-type="pmc-issue-id">502911</issue-id><issue-id pub-id-type="doi">10.1002/ccr3.v14.1</issue-id><elocation-id>e71818</elocation-id><history><date date-type="rev-recd"><day>23</day><month>12</month><year>2025</year></date><date date-type="received"><day>29</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>08</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-09 09:25:14.850"><day>09</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2026 The Author(s). <italic toggle="yes">Clinical Case Reports</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CCR3-14-e71818.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CCR3-14-e71818.pdf"/><abstract><title>ABSTRACT</title><p>Dapagliflozin, though beneficial in heart failure, can rarely cause euglycemic ketoacidosis even in non&#8208;diabetic patients. Clinicians should maintain a high index of suspicion for metabolic acidosis in patients on SGLT2 inhibitors presenting with unexplained illness, regardless of blood glucose level.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ccr371818-kwd-0001">cardiac amyloidosis</kwd><kwd id="ccr371818-kwd-0002">dapagliflozin</kwd><kwd id="ccr371818-kwd-0003">euglycemic ketoacidosis</kwd><kwd id="ccr371818-kwd-0004">non&#8208;diabetic patient</kwd><kwd id="ccr371818-kwd-0005">SGLT2 inhibitors</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="4"/><word-count count="2000"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.8 mode:remove_FC converted:07.01.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ccr371818-cit-1001"><string-name name-style="western"><given-names>S. A. S.</given-names><surname>Hamoud</surname></string-name> and <string-name name-style="western"><given-names>E.</given-names><surname>Harding</surname></string-name>, &#8220;<article-title>Euglycemic Ketoacidosis Induced by Dapagliflozin in a Non&#8208;Diabetic Patient With Cardiac Amyloidosis</article-title>,&#8221; <source>Clinical Case Reports</source><volume>14</volume>, no. <issue>1</issue> (<year>2026</year>): <elocation-id>e71818</elocation-id>, <pub-id pub-id-type="doi">10.1002/ccr3.71818</pub-id>.</mixed-citation>
</p></notes></front><body id="ccr371818-body-0001"><sec id="ccr371818-sec-0001"><label>1</label><title>Introduction</title><p>Sodium&#8211;glucose co&#8208;transporter 2 (SGLT2) inhibitors, including dapagliflozin, canagliflozin, and empagliflozin, have proven benefits in reducing morbidity and mortality in heart failure, regardless of diabetes status [<xref rid="ccr371818-bib-0001" ref-type="bibr">1</xref>, <xref rid="ccr371818-bib-0002" ref-type="bibr">2</xref>]. However, their use carries a risk of euglycemic ketoacidosis (eKA), characterized by significant ketosis and metabolic acidosis without marked hyperglycemia [<xref rid="ccr371818-bib-0003" ref-type="bibr">3</xref>, <xref rid="ccr371818-bib-0004" ref-type="bibr">4</xref>, <xref rid="ccr371818-bib-0005" ref-type="bibr">5</xref>]. Although well described in diabetic populations, reports in non&#8208;diabetics remain scarce [<xref rid="ccr371818-bib-0006" ref-type="bibr">6</xref>, <xref rid="ccr371818-bib-0007" ref-type="bibr">7</xref>].</p><p>Cardiac amyloidosis is a restrictive cardiomyopathy caused by extracellular amyloid fibril deposition, often involving multiple organ systems including the gastrointestinal tract and kidneys [<xref rid="ccr371818-bib-0008" ref-type="bibr">8</xref>, <xref rid="ccr371818-bib-0009" ref-type="bibr">9</xref>]. These effects may predispose to dehydration, reduced oral intake, and autonomic dysfunction, potentially increasing the risk of metabolic complications related to SGLT2 inhibitors.</p></sec><sec id="ccr371818-sec-0002"><label>2</label><title>Case History and Examination</title><p>An 88&#8208;year&#8208;old man with ischaemic heart disease, chronic heart failure (LVEF 45%), moderate mitral regurgitation, pulmonary artery systolic pressure 58&#8201;mmHg, and transthyretin cardiac amyloidosis treated with tafamidis (61&#8201;mg daily) presented with generalized weakness and confusion.</p><p>His daughter reported progressive fatigue and reduced oral intake over several weeks, followed by 4&#8201;days of diarrhea and vomiting. On the day of admission, he developed upper abdominal discomfort and acute confusion. Due to his confusion, a reliable history regarding alcohol consumption could not be obtained.</p><p>He had no history of diabetes. His current medications included dapagliflozin 10&#8201;mg daily (for 5&#8201;months), bumetanide, nicorandil, bisoprolol, apixaban, ranolazine, and tafamidis.</p><p>On examination, he was afebrile, with a blood pressure of 106/60&#8201;mmHg, a heart rate of 105&#8201;bpm (irregularly irregular), and a respiratory rate of 22 breaths per minute. Oxygen saturation was 96% on room air. He appeared dehydrated with dry mucous membranes and reduced skin turgor. Jugular venous pressure was not elevated. Cardiovascular examination revealed an irregular rhythm with a soft systolic murmur at the apex. Abdominal examination was soft with mild epigastric tenderness. No focal neurological deficit was found. ECG revealed new&#8208;onset atrial fibrillation without ST&#8208;T changes.</p><p>Urine culture grew <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Enterococcus faecalis</italic>
</styled-content> sensitive to co&#8208;amoxiclav. HbA1c was 43&#8201;mmol/mol (normal range &lt;&#8201;42&#8201;mmol/mol). Echocardiography showed concentric LV hypertrophy with apical trabeculations consistent with cardiac amyloidosis. His blood tests on admission are summarized in Table&#160;<xref rid="ccr371818-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="ccr371818-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Key investigations.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th><th align="center" valign="bottom" rowspan="1" colspan="1">Result</th><th align="center" valign="bottom" rowspan="1" colspan="1">Reference range</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">pH</td><td align="center" valign="top" rowspan="1" colspan="1">7.16</td><td align="center" valign="top" rowspan="1" colspan="1">7.35&#8211;7.45</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">pCO<sub>2</sub> (kPa)</td><td align="center" valign="top" rowspan="1" colspan="1">5.10</td><td align="center" valign="top" rowspan="1" colspan="1">4.7&#8211;6.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bicarbonate (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">14.1</td><td align="center" valign="top" rowspan="1" colspan="1">22&#8211;28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lactate (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">4.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.5&#8211;2.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glucose (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">10.8</td><td align="center" valign="top" rowspan="1" colspan="1">3.9&#8211;7.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Serum ketones (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anion gap (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">45.6</td><td align="center" valign="top" rowspan="1" colspan="1">8&#8211;16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine (&#956;mol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">141</td><td align="center" valign="top" rowspan="1" colspan="1">64&#8211;104</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sodium (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">137</td><td align="center" valign="top" rowspan="1" colspan="1">133&#8211;146</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Potassium (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">5.5</td><td align="center" valign="top" rowspan="1" colspan="1">3.5&#8211;5.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">eGFR (mL/min/1.73m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">38</td><td align="center" valign="top" rowspan="1" colspan="1">&gt;&#8201;60</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Urea (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">21.1</td><td align="center" valign="top" rowspan="1" colspan="1">2.5&#8211;7.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chloride (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">111</td><td align="center" valign="top" rowspan="1" colspan="1">98&#8211;107</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilirubin (&#956;mol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">1&#8211;20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alanine transaminase (IU/L)</td><td align="center" valign="top" rowspan="1" colspan="1">45</td><td align="center" valign="top" rowspan="1" colspan="1">1&#8211;55</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alkaline phosphatase (IU/L)</td><td align="center" valign="top" rowspan="1" colspan="1">80</td><td align="center" valign="top" rowspan="1" colspan="1">30&#8211;130</td></tr></tbody></table></table-wrap></sec><sec id="ccr371818-sec-0003"><label>3</label><title>Differential Diagnosis, Investigations, and Treatment</title><p>Differential diagnoses included the following:
<list list-type="bullet" id="ccr371818-list-0001"><list-item id="ccr371818-li-0001"><p>eKA secondary to dapagliflozin.</p></list-item><list-item id="ccr371818-li-0002"><p>Starvation ketoacidosis due to poor intake.</p></list-item><list-item id="ccr371818-li-0003"><p>Lactic acidosis from hypoperfusion.</p></list-item><list-item id="ccr371818-li-0004"><p>Sepsis&#8208;related metabolic acidosis from urinary tract infection.</p></list-item><list-item id="ccr371818-li-0005"><p>Mixed metabolic acidosis from multifactorial causes.</p></list-item></list>
</p><p>The diagnosis of eKA was reached based on the triad of metabolic acidosis (high anion gap, low bicarbonate), significant ketonemia, and euglycemia in a patient taking an SGLT2 inhibitor. While sepsis, dehydration, and poor intake were significant contributors, the profound ketosis (3.2&#8201;mmol/L) with only modest hyperglycemia is characteristic of SGLT2 inhibitor&#8208;induced eKA. Starvation ketoacidosis alone was unlikely to cause such severe acidosis, and lactic acidosis, while present, did not fully account for the high anion gap.</p><p>
<italic toggle="yes">Treatment</italic>: The patient was managed per the hospital DKA protocol with intravenous fluid resuscitation (0.9% saline and 10% dextrose infusion) and a fixed&#8208;rate intravenous insulin infusion starting at 6.6&#8201;U/h (0.1 Unit/kg body weight/h). Table&#160;<xref rid="ccr371818-tbl-0002" ref-type="table">2</xref> summarizes the key serial metabolic parameters during treatment. Ketones normalized to 0.8&#8201;mmol/L within 2&#8201;h. Hypoglycemia (glucose 2.7&#8201;mmol/L) developed 6&#8201;h into treatment, prompting a switch to a variable&#8208;rate insulin infusion with 10% dextrose. The metabolic acidosis resolved (pH&#8201;7.33, bicarbonate 16.1&#8201;mmol/L) within 12&#8201;h. Dapagliflozin was discontinued permanently [<xref rid="ccr371818-bib-0001" ref-type="bibr">1</xref>, <xref rid="ccr371818-bib-0002" ref-type="bibr">2</xref>]. Co&#8208;amoxiclav was started for 7&#8201;days for the urinary tract infection.</p><table-wrap position="float" id="ccr371818-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Serial metabolic parameters during treatment&#8212;glucose, ketones, and insulin response.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Date</th><th align="center" valign="bottom" rowspan="1" colspan="1">Time</th><th align="center" valign="bottom" rowspan="1" colspan="1">Glucose (mmol/L)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ketones (mmol/L)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Potassium (mmol/L)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Bicarbonate/pH</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">23/07/25</td><td align="center" valign="top" rowspan="1" colspan="1">15:51</td><td align="center" valign="top" rowspan="1" colspan="1">10.9</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td><td align="center" valign="top" rowspan="1" colspan="1">4.3</td><td align="center" valign="top" rowspan="1" colspan="1">14.9/7.22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">23/07/25</td><td align="center" valign="top" rowspan="1" colspan="1">16:56</td><td align="center" valign="top" rowspan="1" colspan="1">10.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">5.0</td><td align="center" valign="top" rowspan="1" colspan="1">13.8/7.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">23/07/25</td><td align="center" valign="top" rowspan="1" colspan="1">17:56</td><td align="center" valign="top" rowspan="1" colspan="1">11.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.8</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">23/07/25</td><td align="center" valign="top" rowspan="1" colspan="1">20:05</td><td align="center" valign="top" rowspan="1" colspan="1">7.0</td><td align="center" valign="top" rowspan="1" colspan="1">1.1</td><td align="center" valign="top" rowspan="1" colspan="1">4.3</td><td align="center" valign="top" rowspan="1" colspan="1">14.2/7.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">23/07/25</td><td align="center" valign="top" rowspan="1" colspan="1">21:13</td><td align="center" valign="top" rowspan="1" colspan="1">7.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.8</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24/07/25</td><td align="center" valign="top" rowspan="1" colspan="1">00:20</td><td align="center" valign="top" rowspan="1" colspan="1">2.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td><td align="center" valign="top" rowspan="1" colspan="1">3.8</td><td align="center" valign="top" rowspan="1" colspan="1">14.9/7.28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24/07/25</td><td align="center" valign="top" rowspan="1" colspan="1">05:41</td><td align="center" valign="top" rowspan="1" colspan="1">6.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">4.1</td><td align="center" valign="top" rowspan="1" colspan="1">16.1/7.33</td></tr></tbody></table></table-wrap></sec><sec id="ccr371818-sec-0004"><label>4</label><title>Outcome and Follow&#8208;Up</title><p>The patient made a full metabolic recovery and resumed oral intake. He was discharged in stable condition, with dapagliflozin discontinued and sick&#8208;day rules reinforced.</p></sec><sec sec-type="discussion" id="ccr371818-sec-0005"><label>5</label><title>Discussion</title><p>This case illustrates that SGLT2 inhibitors can precipitate eKA in non&#8208;diabetic patients, especially in the presence of acute illness, dehydration, infection, and multi&#8208;organ involvement [<xref rid="ccr371818-bib-0003" ref-type="bibr">3</xref>, <xref rid="ccr371818-bib-0004" ref-type="bibr">4</xref>, <xref rid="ccr371818-bib-0005" ref-type="bibr">5</xref>, <xref rid="ccr371818-bib-0006" ref-type="bibr">6</xref>, <xref rid="ccr371818-bib-0007" ref-type="bibr">7</xref>]. SGLT2 inhibitors promote glycosuria and impair glucose reabsorption, leading to lower blood glucose. Concurrently, they stimulate glucagon secretion, enhance lipolysis, and promote hepatic ketogenesis [<xref rid="ccr371818-bib-0003" ref-type="bibr">3</xref>, <xref rid="ccr371818-bib-0004" ref-type="bibr">4</xref>]. In a metabolically stressed state (e.g., from infection, dehydration), insulin secretion may be suppressed, further tipping the balance toward ketogenesis. It is important to note that while the term &#8220;euglycemic DKA&#8221; is widely used, recent consensus [<xref rid="ccr371818-bib-0007" ref-type="bibr">7</xref>] specifies DKA typically occurs in individuals with diabetes. As our patient was non&#8208;diabetic, his presentation is more accurately described as SGLT2 inhibitor&#8208;induced euglycemic ketosis, a critical differential for metabolic acidosis that falls outside traditional diagnostic guidelines. In this patient, prolonged diarrhea, vomiting, and a urinary tract infection created a perfect metabolic storm. His advanced age, associated with an age&#8208;related decline in beta&#8208;cell function, may have further reduced his metabolic reserve. Cardiac amyloidosis likely contributed via gastrointestinal dysmotility, malabsorption, and autonomic dysfunction, increasing susceptibility to dehydration and impaired metabolic adaptation [<xref rid="ccr371818-bib-0008" ref-type="bibr">8</xref>, <xref rid="ccr371818-bib-0009" ref-type="bibr">9</xref>, <xref rid="ccr371818-bib-0010" ref-type="bibr">10</xref>].</p><p>The initial high&#8208;dose insulin infusion, based on a standard DKA protocol, led to rapid ketone clearance but also hypoglycemia. This highlights a key management difference in SGLT2 inhibitor&#8208;induced eKA in non&#8208;diabetics. These patients have preserved endogenous insulin secretion and sensitivity. Therefore, the ketoacidosis is often exquisitely sensitive to therapy, and vigorous fluid resuscitation alone or with very low&#8208;dose insulin (e.g., 0.05&#8201;U/kg/h) is frequently sufficient, minimizing hypoglycemia risk [<xref rid="ccr371818-bib-0007" ref-type="bibr">7</xref>, <xref rid="ccr371818-bib-0011" ref-type="bibr">11</xref>]. The profound ketosis in our patient resolved quickly, but the standard insulin dose proved excessive, underscoring the need for a tailored approach. Bicarbonate correction typically lags behind pH improvement during treatment of ketoacidosis due to normal physiological mechanisms. Once insulin suppresses ketogenesis, pH rises quickly as respiratory compensation decreases and pCO<sub>2</sub> normalizes. However, bicarbonate regenerates more slowly because it depends on hepatic metabolism of ketoacids, renal recovery of bicarbonate reabsorption, and resolution of a transient hyperchloremic acidosis caused by saline resuscitation [<xref rid="ccr371818-bib-0012" ref-type="bibr">12</xref>]. This delayed bicarbonate rise is expected and does not indicate treatment failure.</p><p>As heart failure guidelines now endorse SGLT2 inhibitors in non&#8208;diabetic patients [<xref rid="ccr371818-bib-0001" ref-type="bibr">1</xref>, <xref rid="ccr371818-bib-0002" ref-type="bibr">2</xref>], awareness of this rare but potentially life&#8208;threatening complication is vital.</p></sec><sec id="ccr371818-sec-0006"><label>6</label><title>Search Strategy</title><p>A literature search (PubMed, Embase, and Google Scholar; up to August 2025) using combinations of the keywords &#8216;euglycaemic ketoacidosis&#8217;, &#8216;euDKA&#8217;, &#8216;SGLT2 inhibitors&#8217;, &#8216;dapagliflozin&#8217;, &#8216;non&#8208;diabetic,&#8217; and &#8216;cardiac amyloidosis&#8217; revealed multiple euDKA reports in diabetic patients [<xref rid="ccr371818-bib-0003" ref-type="bibr">3</xref>, <xref rid="ccr371818-bib-0004" ref-type="bibr">4</xref>, <xref rid="ccr371818-bib-0005" ref-type="bibr">5</xref>, <xref rid="ccr371818-bib-0006" ref-type="bibr">6</xref>], a small number in non&#8208;diabetics [<xref rid="ccr371818-bib-0002" ref-type="bibr">2</xref>, <xref rid="ccr371818-bib-0006" ref-type="bibr">6</xref>], but no previous reports linking dapagliflozin&#8208;induced eKA with cardiac amyloidosis.</p></sec><sec id="ccr371818-sec-0007"><label>7</label><title>How This Report Adds to the Literature</title><p>
<list list-type="bullet" id="ccr371818-list-0002"><list-item id="ccr371818-li-0006"><p>Novel association: First report of dapagliflozin&#8208;induced euglycemic ketosis in a non&#8208;diabetic patient with transthyretin amyloidosis.</p></list-item><list-item id="ccr371818-li-0007"><p>Risk factors: Highlights how systemic amyloidosis may increase vulnerability to metabolic decompensation [<xref rid="ccr371818-bib-0008" ref-type="bibr">8</xref>, <xref rid="ccr371818-bib-0009" ref-type="bibr">9</xref>, <xref rid="ccr371818-bib-0010" ref-type="bibr">10</xref>].</p></list-item><list-item id="ccr371818-li-0008"><p>Clinical implication: Reinforces the critical need for sick&#8208;day guidance, close monitoring, and consideration of euglycemic ketosis during intercurrent illness in all patients on SGLT2 inhibitors [<xref rid="ccr371818-bib-0001" ref-type="bibr">1</xref>, <xref rid="ccr371818-bib-0002" ref-type="bibr">2</xref>].</p></list-item></list>
</p></sec><sec id="ccr371818-sec-0008"><label>8</label><title>Learning Points</title><p>
<list list-type="order" id="ccr371818-list-0003"><list-item id="ccr371818-li-0009"><p>eKA can occur in non&#8208;diabetic patients treated with SGLT2 inhibitors.</p></list-item><list-item id="ccr371818-li-0010"><p>A high index of suspicion is required as the presentation can be masked by normal or only slightly elevated blood glucose.</p></list-item><list-item id="ccr371818-li-0011"><p>Management should prioritize fluid resuscitation with low dose insulin (0.05&#8201;U/KG/h) due to insulin sensitivity.</p></list-item><list-item id="ccr371818-li-0012"><p>Cardiac amyloidosis with its multi&#8208;system involvement may increase risk through systemic and metabolic vulnerability.</p></list-item><list-item id="ccr371818-li-0013"><p>Sick&#8208;day rules should be emphasized for all patients on SGLT2 inhibitors.</p></list-item></list>
</p></sec><sec id="ccr371818-sec-0013"><title>Author Contributions</title><p>
<bold>Salhamoud Abdelfatah Saleh Hamoud:</bold> conceptualization, supervision, writing &#8211; original draft, writing &#8211; review and editing. <bold>Ellie Harding:</bold> data curation, resources, writing &#8211; original draft.</p></sec><sec id="ccr371818-sec-5004"><title>Funding</title><p>The authors have nothing to report.</p></sec><sec sec-type="conclusions" id="ccr371818-sec-0009"><title>Consent</title><p>Written informed consent for publication was obtained from the patient.</p></sec></body><back><ack id="ccr371818-sec-0010"><title>Acknowledgments</title><p>The authors thank the clinical teams involved in the care of the patient and the medical records department at University Hospitals Plymouth NHS Trust for their assistance.</p></ack><sec sec-type="data-availability" id="ccr371818-sec-0012"><title>Data Availability Statement</title><p>The data that support the findings of this study are available within the article.</p></sec><ref-list content-type="cited-references" id="ccr371818-bibl-0001"><title>References</title><ref id="ccr371818-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ccr371818-cit-0001"><string-name name-style="western"><given-names>P. A.</given-names><surname>Heidenreich</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Bozkurt</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Aguilar</surname></string-name>, et&#160;al., &#8220;<article-title>AHA/ACC/HFSA Guideline for the Management of Heart Failure</article-title>,&#8221; <source>Journal of the American College of Cardiology</source><volume>79</volume>, no. <issue>17</issue> (<year>2022</year>): <fpage>e263</fpage>&#8211;<lpage>e421</lpage>.<pub-id pub-id-type="pmid">35379503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2021.12.012</pub-id></mixed-citation></ref><ref id="ccr371818-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ccr371818-cit-0002"><string-name name-style="western"><given-names>D.</given-names><surname>Fitchett</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Zinman</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wanner</surname></string-name>, et&#160;al., &#8220;<article-title>Heart Failure Outcomes With Empagliflozin in Patients With or Without Diabetes: EMPA&#8208;REG OUTCOME Trial</article-title>,&#8221; <source>European Heart Journal</source><volume>37</volume>, no. <issue>19</issue> (<year>2016</year>): <fpage>1526</fpage>&#8211;<lpage>1534</lpage>.<pub-id pub-id-type="pmid">26819227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehv728</pub-id><pub-id pub-id-type="pmcid">PMC4872285</pub-id></mixed-citation></ref><ref id="ccr371818-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ccr371818-cit-0003"><string-name name-style="western"><given-names>S. I.</given-names><surname>Taylor</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Blau</surname></string-name>, and <string-name name-style="western"><given-names>K. I.</given-names><surname>Rother</surname></string-name>, &#8220;<article-title>SGLT2 Inhibitors May Predispose to Ketoacidosis</article-title>,&#8221; <source>Journal of Clinical Endocrinology and Metabolism</source><volume>100</volume>, no. <issue>8</issue> (<year>2015</year>): <fpage>2849</fpage>&#8211;<lpage>2852</lpage>.<pub-id pub-id-type="pmid">26086329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2015-1884</pub-id><pub-id pub-id-type="pmcid">PMC4525004</pub-id></mixed-citation></ref><ref id="ccr371818-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ccr371818-cit-0004"><string-name name-style="western"><given-names>A. L.</given-names><surname>Peters</surname></string-name>, <string-name name-style="western"><given-names>E. O.</given-names><surname>Buschur</surname></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Buse</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Cohan</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Diner</surname></string-name>, and <string-name name-style="western"><given-names>I. B.</given-names><surname>Hirsch</surname></string-name>, &#8220;<article-title>Euglycaemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium&#8211;Glucose Cotransporter 2 Inhibition</article-title>,&#8221; <source>Diabetes Care</source><volume>38</volume>, no. <issue>9</issue> (<year>2015</year>): <fpage>1687</fpage>&#8211;<lpage>1693</lpage>.<pub-id pub-id-type="pmid">26078479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc15-0843</pub-id><pub-id pub-id-type="pmcid">PMC4542270</pub-id></mixed-citation></ref><ref id="ccr371818-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ccr371818-cit-0005"><string-name name-style="western"><given-names>J.</given-names><surname>Rosenstock</surname></string-name> and <string-name name-style="western"><given-names>E.</given-names><surname>Ferrannini</surname></string-name>, &#8220;<article-title>Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors</article-title>,&#8221; <source>Diabetes Care</source><volume>38</volume>, no. <issue>9</issue> (<year>2015</year>): <fpage>1638</fpage>&#8211;<lpage>1642</lpage>.<pub-id pub-id-type="pmid">26294774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc15-1380</pub-id></mixed-citation></ref><ref id="ccr371818-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ccr371818-cit-0006"><string-name name-style="western"><given-names>M.</given-names><surname>Thawabi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Studyvin</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Jumean</surname></string-name>, et&#160;al., &#8220;<article-title>Euglycaemic Ketoacidosis in a Non&#8208;Diabetic Patient on Empagliflozin for Heart Failure With Reduced Ejection Fraction</article-title>,&#8221; <source>Journal of Community Hospital Internal Medicine Perspectives</source><volume>11</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>288</fpage>&#8211;<lpage>291</lpage>.</mixed-citation></ref><ref id="ccr371818-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ccr371818-cit-0007"><string-name name-style="western"><given-names>M. S.</given-names><surname>Eledrisi</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Beshyah</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Malik</surname></string-name>, et&#160;al., &#8220;<article-title>Management of Diabetic Ketoacidosis: A Consensus Statement of the Arab Society of Paediatric and Adult Endocrinology and Diabetes (ASPAED)</article-title>,&#8221; <source>Diabetes Research and Clinical Practice</source><volume>8</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>165</fpage>&#8211;<lpage>173</lpage>.</mixed-citation></ref><ref id="ccr371818-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ccr371818-cit-0008"><string-name name-style="western"><given-names>M. S.</given-names><surname>Maurer</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Elliott</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Comenzo</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Semigran</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Rapezzi</surname></string-name>, &#8220;<article-title>Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis</article-title>,&#8221; <source>Circulation</source><volume>135</volume>, no. <issue>14</issue> (<year>2017</year>): <fpage>1357</fpage>&#8211;<lpage>1377</lpage>.<pub-id pub-id-type="pmid">28373528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.116.024438</pub-id><pub-id pub-id-type="pmcid">PMC5392416</pub-id></mixed-citation></ref><ref id="ccr371818-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ccr371818-cit-0009"><string-name name-style="western"><given-names>F. L.</given-names><surname>Ruberg</surname></string-name> and <string-name name-style="western"><given-names>J. L.</given-names><surname>Berk</surname></string-name>, &#8220;<article-title>Transthyretin [TTR] Cardiac Amyloidosis</article-title>,&#8221; <source>Circulation</source><volume>126</volume>, no. <issue>10</issue> (<year>2012</year>): <fpage>1286</fpage>&#8211;<lpage>1300</lpage>.<pub-id pub-id-type="pmid">22949539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.111.078915</pub-id><pub-id pub-id-type="pmcid">PMC3501197</pub-id></mixed-citation></ref><ref id="ccr371818-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ccr371818-cit-0010"><string-name name-style="western"><given-names>O. K.</given-names><surname>Siddiqi</surname></string-name> and <string-name name-style="western"><given-names>F. L.</given-names><surname>Ruberg</surname></string-name>, &#8220;<article-title>Cardiac Amyloidosis: An Update on Pathophysiology, Diagnosis, and Treatment</article-title>,&#8221; <source>Trends in Cardiovascular Medicine</source><volume>28</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>10</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">28739313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcm.2017.07.004</pub-id><pub-id pub-id-type="pmcid">PMC5741539</pub-id></mixed-citation></ref><ref id="ccr371818-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ccr371818-cit-0011"><string-name name-style="western"><given-names>L.</given-names><surname>Monnier</surname></string-name> and <string-name name-style="western"><given-names>G.</given-names><surname>Bock</surname></string-name>, &#8220;<article-title>Euglycaemic Ketoacidosis in a Non&#8208;Diabetic Patient on SGLT2 Inhibitor: A Case Report and Pathophysiological Insights</article-title>,&#8221; <source>Journal of Clinical Endocrinology and Metabolism</source><volume>107</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>e1334</fpage>&#8211;<lpage>e1337</lpage>.</mixed-citation></ref><ref id="ccr371818-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ccr371818-cit-0012"><string-name name-style="western"><given-names>A. E.</given-names><surname>Kitabchi</surname></string-name>, <string-name name-style="western"><given-names>G. E.</given-names><surname>Umpierrez</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Miles</surname></string-name>, and <string-name name-style="western"><given-names>J. N.</given-names><surname>Fisher</surname></string-name>, &#8220;<article-title>Hyperglycaemic Crisis in Adult Patients With Diabetes</article-title>,&#8221; <source>Diabetes Care</source><volume>32</volume>, no. <issue>7</issue> (<year>2009</year>): <fpage>1335</fpage>&#8211;<lpage>1343</lpage>.<pub-id pub-id-type="pmid">19564476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc09-9032</pub-id><pub-id pub-id-type="pmcid">PMC2699725</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>